行情

MDXG

MDXG

MIMEDX GROUP
NASDAQ

实时行情|Nasdaq Last Sale

4.840
+0.250
+5.45%
盘后: 4.840 0 0.00% 16:47 01/24 EST
开盘
4.540
昨收
4.590
最高
4.900
最低
4.420
成交量
85.23万
成交额
168.45万
52周最高
15.99
52周最低
4.420
市值
5.43亿
市盈率(TTM)
-15.0404
分时
5日
1月
3月
1年
5年
MDXG: Model Updates
By John Vandermosten, CFA NASDAQ:MDXG READ THE FULL MDXG RESEARCH REPORT Updates Based on Guidance We had a chance to catch up with MiMedx Group, Inc. (NASDAQ:MDXG) management following their issuance of 2022 guidance and discussions with investors at Janu...
Zacks Small Cap Research · 4天前
Short-Seller Cohodes Sues MiMedx Over Wiretap, Defamation Claims
Bloomberg · 5天前
Next Capital Management LLC Buys Globus Medical Inc, Tesla Inc, PPG Industries Inc, Sells Apple ...
Investment company Next Capital Management LLC (Current Portfolio) buys Globus Medical Inc, Tesla Inc, PPG Industries Inc, CSG Systems International Inc, iShares Core MSCI Emerging Markets ETF, sells Apple Inc, Nuveen Floating Rate Income Fund, Blackrock F...
GuruFocus.com · 01/14 18:38
MDXG: New Year's Resolutions
By John Vandermosten, CFA NASDAQ:MDXG READ THE FULL MDXG RESEARCH REPORT
Benzinga · 01/12 15:50
MDXG:新年决议
By John Vandermosten, CFA NASDAQ:MDXG READ THE FULL MDXG RESEARCH REPORT Key Strategic Milestones for 2022 On January 10, 2022, MiMedx Group, Inc. (NASDAQ:MDXG) reiterated its 2021 accomplishments and announced its 2022 initiatives and guidance. With the r...
Zacks Small Cap Research · 01/12 10:20
MiMedx sees 2022 annual revenue growth of 11%-14%, outlines key strategic milestones for 2022
MiMedx Group (MDXG -4.6%) expects strong, double-digit growth in 2022 to be driven by treatment transformation, including advancement into the Surgical Recovery market, global expansion with the launch of EPIFIX® in Japan anticipated for
Seekingalpha · 01/10 19:41
MIMEDX Sees FY22 Annual Revenue Growth Of 11%-14%; Sees Advanced Wound Care/Section 361 Adj. Revenue $236M-$240M
2022 Outlook The Company provides the following financial outlook for 2022: Annual revenue growth of 11% to 14% in the Company's continuing portfolio of
Benzinga · 01/10 13:16
MIMEDX Outlines Key Strategic Milestones for 2022
MIMEDX Primed to Commence Pivotal Phase 3 Clinical Study Program of micronized dehydrated Human Amnion Chorion Membrane (mdHACM) in Knee Osteoarthritis (KOA), Targeting Potential Late-2026 Commercial Launch Double-Digit Growth Objective in 2022 to be Drive...
GlobeNewswire · 01/10 13:00
更多
财务预测
实际值(美元)
预测值(美元)
利润表更多
净利润(美元)
同比(%)
资产负债表更多
总资产(美元)
总负债(美元)
资产负债率(%)
现金流表更多
经营现金流(美元)
同比(%)
了解MDXG最新的财务预测,通过MDXG每股收益,每股净资产,每股现金流等数据分析MIMEDX GROUP近期的经营情况,然后做出明智的投资选择。
分析师评级

2位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

0.00%强力推荐
100.00%买入
0.00%中性
0.00%落后大盘
0.00%卖出
目标价格预测
分析师预测MDXG价格均价为14.50,最高价位23.00,最低价为8.50。
最高23.00
均价14.50
最低8.50
现价4.840
EPS
实际EPS
预期EPS
-0.15-0.11-0.08-0.04
Q4 2020
Q1 2021
Q2 2021
Q3 2021
Q4 2021
机构持股
总机构数: 167
机构持股: 5,950.64万
持股比例: 53.06%
总股本: 1.12亿
类型机构数股数
增持
35
207.50万
建仓
29
151.47万
减持
38
384.07万
平仓
22
176.04万
  • 业绩
  • 资产分布
  • 分红历史
暂无数据
所属板块
生物技术和医学研究
+1.12%
制药与医学研究
-0.55%
高管信息
Non-Executive Chairman/Independent Director
M. Kathleen Behrens Wilsey
Chief Executive Officer/Director
Timothy Wright
Chief Financial Officer/Executive Vice President - Finance
Peter Carlson
Executive Vice President
Rohit Kashyap
Executive Vice President
Robert Stein
Senior Vice President/Chief Compliance Officer
Mark Graves
Senior Vice President/Director of Investor Relations
Jack Howarth
Senior Vice President
Scott Turner
General Counsel/Secretary
William Hulse
Director
Phyllis Gardner
Independent Director
James Bierman
Independent Director
Michael Giuliani
Independent Director
William Hawkins
Independent Director
Cato Laurencin
Independent Director
K. Todd Newton
Independent Director
Martin Sutter
暂无数据
MDXG 简况
MiMedx Group Inc是一家利用羊膜组织作为再生医学平台,为多个医疗保健领域开发和分销胎盘组织同种异体移植物的公司。该公司专注于满足急性和慢性伤口不愈合患者的需求,并致力于为退行性肌肉骨骼疾病患者提供减轻疼痛和改善功能的研发末期新药。公司的平台技术包括“AmnioFix”、“EpiFix”、“EpiCord”、“AmnioCord”和“AmnioFill”。其“AmnioFix”和“EpiFix”是来自人类胎盘膜的羊膜和绒毛膜层的组织同种异体移植物。“EpiCord”和“AmnioCord”是源自脐带组织的组织同种异体移植物。“AmnioFill”是一种颗粒状产品,由胎盘结缔组织基质组成,来源于胎盘和胎盘膜。

微牛提供MiMedx Group Inc(NASDAQ-MDXG)的股票价格、实时市场报价、专业分析师评级、深度图表和免费的MDXG股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易MDXG股票基本功能。